What it is and how it works
From the published literature on Orexin A and B; the papers are listed at the end. Research summary, not a recommendation.
What it is
Orexin A and orexin B (also called hypocretin-1 and hypocretin-2) are two neuropeptides made by a small cluster of nerve cells in the hypothalamus, the brain region that controls sleep, appetite and body temperature. Orexin A has 33 amino acids and orexin B has 28; both are cut from one precursor protein. They were discovered independently by two research groups in 1998. Neither peptide is an approved drug, but medicines that block their receptors are approved for insomnia.
How it works
Orexins act on two receptors on nerve cells, the orexin-1 and orexin-2 receptors, which are G protein-coupled receptors (surface switches that change a cell's activity when a signal binds). Orexin neurons send fibres to the brain's arousal centres and keep them active, which stabilises wakefulness and prevents sudden slips into sleep or into REM (dreaming) sleep. In narcolepsy type 1 most orexin neurons are lost, which causes daytime sleepiness and cataplexy (sudden loss of muscle tone triggered by emotion). Orexin also raises activity of the sympathetic nervous system, the fight-or-flight system that tightens blood vessels. Drugs such as suvorexant work the opposite way, blocking both receptors to make sleep easier.
What it has been studied for
- Control of sleep and wakefulness (discovery and review literature)
- Narcolepsy type 1, caused by loss of orexin neurons (human brain studies)
- Insomnia treatment with orexin receptor blockers such as suvorexant (phase 3 trials)
- Intranasal orexin A for sleep stability and attention in narcolepsy (small human crossover trial)
- Intranasal orexin A and sympathetic nerve activity (small human pilot trial)
Strength of the evidence
Early human studiesOrexin A itself has only small placebo-controlled crossover studies given into the nose, while the receptor-blocking drugs that act on the same system are approved medicines.
What the literature reports on safety
The small intranasal studies reported no serious adverse effects, but they were short and in few subjects, and one found that orexin A raised sympathetic nerve activity in blood vessels, so blood-pressure effects are a theoretical concern. Orexin A and B are not FDA approved; the approved drugs in this system (suvorexant, lemborexant, daridorexant) are receptor blockers, carry warnings for next-day drowsiness and are controlled substances. Orexin peptides sold online are research chemicals with no regulatory review of quality.
Key papers
The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness (opens in a new tab)
Review · Sakurai T · Nature Reviews Neuroscience (2007) · PMID 17299454
Reviewed how orexin neurons connect to the brain's arousal and sleep centres and how this circuit keeps wakefulness stable.
Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment (opens in a new tab)
Review · Bassetti CLA, Adamantidis A, et al. · Nature Reviews Neurology (2019) · PMID 31324898
Reviewed narcolepsy and described type 1 as a disorder caused by loss of orexin-producing neurons, likely through an immune attack.
Randomized trial · Herring WJ, Connor KM, et al. · Biological Psychiatry (2016) · PMID 25526970
In two pivotal phase 3 trials with about two thousand patients, the orexin receptor blocker suvorexant improved sleep onset and total sleep time over placebo and was generally well tolerated.
Randomized trial · Weinhold SL, Seeck-Hirschner M, et al. · Behavioural Brain Research (2014) · PMID 24406723
In a placebo-controlled crossover study of 14 people with narcolepsy, intranasal orexin A reduced wake-to-REM transitions and attention errors.
Randomized trial · Meusel M, Voß J, et al. · Journal of Neurophysiology (2022) · PMID 35044844
In a double-blind crossover pilot in 10 healthy men, intranasal orexin A increased sympathetic nerve activity to blood vessels without changing blood pressure or heart rate.
Reduced number of hypocretin neurons in human narcolepsy (opens in a new tab)
Case series · Thannickal TC, Moore RY, et al. · Neuron (2000) · PMID 11055430
Post-mortem brains of people with narcolepsy had far fewer orexin (hypocretin) neurons than control brains.
Animal study · Sakurai T, Amemiya A, et al. · Cell (1998) · PMID 9491897
Discovered orexin A and B and their two receptors in the rat hypothalamus and reported that giving them into the brain increased feeding.
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity (opens in a new tab)
Animal study · de Lecea L, Kilduff TS, et al. · Proceedings of the National Academy of Sciences of the USA (1998) · PMID 9419374
Independently identified the same two peptides, named them hypocretins, and showed they excited nerve cells.
Sources checked: PubMed/PMC (E-utilities esummary and abstracts on every PMID), FDA labels for the orexin receptor antagonists (safety_notes only), written 2026-11-06.
No sources yet
None of the three teachers' sources we have indexed discuss Orexin A and B yet. This page will fill in as sources are added.
Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.
Disclaimer: for research purposes only
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.